Imipenem/Cilastatin Kabi

Imipenem, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as an intravenous powder for reconstitution for IV use. It treats severe infections caused by susceptible bacteria in adult and pediatric patients and is indicated for a range of serious bacterial infections.

GNH USA supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, ensuring quality and regulatory compliance across global markets.

Imipenem/Cilastatin is a carbapenem antibiotic used to treat infections caused by susceptible bacteria across several organ systems. - Severe systemic infections: provides bactericidal activity against a broad spectrum of Gram‑negative and Gram‑positive pathogens. - Intra‑abdominal infections: eradicates polymicrobial organisms involved in complicated abdominal sepsis. - Urinary tract infections: clears resistant uropathogens in complicated UTIs. - Skin and soft‑tissue infections: treats cellulitis and wound infections caused by susceptible bacteria. - Pneumonia: effective against community‑acquired and hospital‑acquired bacterial pneumonia. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Imipenem/Cilastatin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Infusion site phlebitis - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Anaphylaxis or severe allergic reactions - Clostridioides difficile‑associated colitis - Thrombocytopenia or neutropenia - Acute renal failure - Hepatotoxicity

When prescribing Imipenem/Cilastatin, clinicians should consider several safety precautions to minimize risk. - Renal function: assess and adjust dose in patients with impaired kidney function. - Seizure risk: monitor patients with a history of seizures or CNS disorders. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactam antibiotics. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications that may affect renal clearance or seizure threshold. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Imipenem/Cilastatin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Valproic acid: concomitant use markedly reduces valproate plasma concentrations, risking loss of seizure control. - CNS stimulants (e.g., phenobarbital, high‑dose carbamazepine): may increase the likelihood of seizures.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance renal clearance, necessitating dose adjustment. - Aminoglycosides: combined use can increase nephrotoxicity. - Warfarin: may alter INR, requiring closer coagulation monitoring. - Oral contraceptives: carbapenems may reduce hormonal efficacy, advise alternative contraception.